Due to its tumor-related overexpression and ability to induce humoral and/or cellular immune responses, ENO1 has already been classified as a tumor-associated Ag in solid cancers, such as pancreatic ductal adenocarcinoma (PDA) [12, 33]. Here, ENO1 is linked to Patent ductus arteriosus.